10-KPeriod: FY2004

CVS HEALTH Corp Annual Report, Year Ended Jan 3, 2004

Filed March 12, 2004For Securities:CVS

Summary

CVS Corporation's 2003 Form 10-K report highlights a strong financial year characterized by significant revenue growth and an expanding store footprint. The company is solidifying its position as the second-largest retail drugstore chain in the U.S., driven by its dual focus on the Retail Pharmacy and Pharmacy Benefit Management (PBM) segments. The Retail Pharmacy, representing approximately 95% of sales, saw continued strength from prescription drug sales, which are growing at a faster rate than front-store merchandise. Strategic investments in technology and customer loyalty programs like ExtraCare are key drivers of this success. Furthermore, CVS is actively pursuing expansion through new store openings and relocations, particularly in new markets, demonstrating a commitment to increasing market share and accessibility. The PBM segment, operating under PharmaCare Management Services, also contributes to the company's diversified revenue stream, managing a significant number of lives and offering specialty pharmacy services. While facing competition, CVS leverages its operational efficiency, strong supplier relationships, and strategic store development to maintain its competitive edge and deliver value to shareholders.

Key Highlights

  • 1Achieved net sales of $26.6 billion in 2003, establishing CVS as the second-largest retail drugstore chain in the U.S.
  • 2Operated 4,179 retail and specialty pharmacy stores across 32 states and D.C., holding number one or two market share in 62% of its operating markets.
  • 3Prescription drug sales represented 69% of net sales in 2003, showing a consistent growth trend and outpacing front-store sales.
  • 4Invested significantly in technology, including the EPIC system for pharmacy workflow and the Assisted Inventory Management (AIM) system, to enhance efficiency and customer service.
  • 5Expanded its ExtraCare loyalty program to 44 million members, a key initiative for customer retention and personalized marketing.
  • 6Opened 150 new stores and relocated 125 in 2003, with plans to open approximately 225-250 new or relocated stores in 2004, including expansion into new markets.
  • 7Managed approximately 15 million lives through its PharmaCare Management Services (PBM) segment, which includes specialty pharmacy operations.

Frequently Asked Questions

CVS Corporation operates primarily through two segments: Retail Pharmacy and Pharmacy Benefit Management (PBM). The Retail Pharmacy segment, which accounts for about 95% of sales, includes traditional drugstores selling prescription drugs and general merchandise. The PBM segment, under PharmaCare Management Services, provides prescription benefit management services to managed care organizations and offers specialty pharmacy services. Revenue is generated from prescription sales, front-store merchandise, and PBM services.

CVS Corporation focuses on store development through opening new stores, relocating existing ones to more convenient sites, and entering new geographic markets. In 2003, they opened 150 new stores and relocated 125, with plans for 225-250 new or relocated stores in 2004, including a significant number in new markets like Chicago, Las Vegas, and Phoenix. This strategy aims to increase market share and accessibility.

Technology is a critical component of CVS's strategy to enhance customer service and operational efficiency. Key systems include the EPIC system for pharmacy workflow and the Assisted Inventory Management (AIM) system for inventory control. The ExtraCare card program is a major loyalty initiative, with 44 million members, designed to reward customers, drive sales through customized offers, and provide valuable customer data for marketing efforts.

For the fiscal year ended January 3, 2004, CVS reported net sales of $26.6 billion, a significant increase from the previous year. Operating profit was $1.42 billion, and net earnings were $847.3 million, resulting in diluted earnings per share of $2.06. The company demonstrated growth in both its retail and PBM segments, with prescription drug sales continuing to be a primary driver.